anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
There are five patient cohort groups. Each will receive a progressively higher starting dose of phenelzine sulfate, consecutively. Cohort A will start at 15mg/day and will be increased to 30mg/d by week 2 and further increased to 45mg/d for week 3, which will be maintained throughout the study. Cohort B will start at 45mg/d and will be held constant throughout the Study. Similarly, Cohort C, D \& E will start at 60, 75 and 90mg/d, respectively, and will also be held on this dose throughout the study. The decision to escalate the dose for the next cohort will be made on the basis of the number of dose limiting toxicity (DLT) events observed during the first 8 weeks in the preceding cohort group. In addition, all cohort groups will receive a constant dose of Abraxane at 100mg/m2.
Single and multiple doses of 15 mg or more of univasc ® gives sustained inhibition of plasma ACE activity of 80-90%, beginning within 2 hours and lasting 24 hours (80%). 

In controlled trials, the peak effects of orally administered moexipril increased with the dose administered over a dose range of 7.5 to 60 mg, given once a day. Antihypertensive effects were first detectable about 1 hour after dosing, with a peak effect between 3 and 6 hours after dosing. Just before dosing (i.e., at trough), the antihypertensive effects were less prominently related to dose and the antihypertensive effect tended to diminish during the 24-hour dosing interval when the drug was administered once a day.

In multiple dose studies in the dose range of 7.5 to 30 mg once daily, univasc ® lowered sitting diastolic and systolic blood pressure effects at trough by 3 to 6 mmHg and 4 to 11 mmHg more than placebo, respectively. There was a tendency toward increased response with higher doses over this range. These effects are typical of ACE inhibitors but, to date, there are no trials of adequate size comparing moexipril with other antihypertensive agents. 

The trough diastolic blood pressure effects of moexipril were approximately 3 to 6 mmHg in various studies. Generally, higher doses of moexipril leave a greater fraction of the peak blood pressure effect still present at trough. During dose titration, any decision as to the adequacy of a dosing regimen should be based on trough blood pressure measurements. If diastolic blood pressure control is not adequate at the end of the dosing interval, the dose can be increased or given as a divided (BID) regimen.

During chronic therapy, the antihypertensive effect of any dose of univasc ® is generally evident within 2 weeks of treatment, with maximal reduction after 4 weeks. The antihypertensive effects of univasc ® have been proven to continue during therapy for up to 24 months. 

univasc ®, like other ACE inhibitors, is less effective in decreasing trough blood pressures in blacks than in non-blacks. Placebo-corrected trough group mean diastolic blood pressure effects in blacks in the proposed dose range varied between +1 to -3 mmHg compared with responses in non-blacks of -4 to -6 mmHg. 

The effectiveness of univasc ® was not significantly influenced by patient age, gender, or weight. univasc ® has been shown to have antihypertensive activity in both pre- and postmenopausal women who have participated in placebo-controlled clinical trials. 

Formal interaction studies with moexipril have not been carried out with antihypertensive agents other than thiazide diuretics. In these studies, the added effect of moexipril was similar to its effect as monotherapy. In general, ACE inhibitors have less than additive effects with beta-adrenergic blockers, presumably because both work by inhibiting the renin-angiotensin system.
Formulations for controlled, prolonged release of GM-CSF have been developed.  These are based on solid microparticles formed of the combination of biodegradable, synthetic polymers such as poly(lactic acid) (PLA), poly(glycolic acid) (PGA), and copolymers thereof with excipients and drug loadings that yield zero order or first order release, or multiphasic release over a period of approximately three to twenty-one days, preferably one week, when administered by injection. In the preferred embodiment, the microparticles are microspheres having diameters in the range of 10 to 60 microns, formed of a blend of PLGA  having different molecular weights, most preferably 6,000, 30,000 and 41,000. Other embodiments have been developed to alter the release kinetics or the manner in which the drug is distributed in vivo. For example, in some cases a polymer is selected which elicits a mild inflammatory reaction, for example, PLGA and polyanhydrides can act as chemoattractant, either due to the polymer itself or minor contaminants in the polymer, or polymers which are bioadhesive are used for transmucosal or oral delivery. In another embodiment, the GM-CSF is administered in a hydrogel which can be injected subcutaneous or at a specific site for controlled release. The microparticles or hydrogel are administered to the patient in an amount effective to stimulate proliferation of hematopoietic cells, especially white cells.
TAK-625 200 mcg per kilogram, orally, once daily for 1 week. After that, TAK-625 400 mcg per kilogram, orally, once daily after Week 1.
PURPOSE:A protecting agent for making skin soft, keeping the softness of the skin and providing it with effect of moisture retention, obtained by blending an essence extracted from the rhizome of Coix Ma-yuen Roman of the genus Coix, a parennial gramineous plant, with carbolic acid, sodium secondary phosphate, water and a water absorbing agent. CONSTITUTION:A protecting agent for making skin soft is obtained by blending 0.1-0.2wt% essence obtained by extrating the rhizome of Coix Ma-yuen Roman with 0.1-0.2wt% carbolic acid, 1.0-2.0wt% sodium secondary phosphate and water in an amount to give 100wt% total substances. The essence contains various kinds of sitosterols, etc. in fatty oils, remedies congestion, hemostasis, and inflammation, and has effects on the softening and absorption of the induration of skin tissue and on the activation of cell. The protecting agent for making skin soft is weakly acidic (ph7-9), showing excellent effect on the preservation of the skin and the conservation of elasticity by the modification of the keratin layer of the skin and synergistic effects of emollient effect, increase in blood stream, exasperation of metabolism, etc. The agent may be blended with a water absorbing agent (e.g., organometallic compound) as a component.
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to wound-healing agents and can be used for healing burns. Medicinal agent comprises an antibacterial substance that is made as powder. As an antibacterial substance calcium carbonate CaCO 3  and calcium hydrocarbonate Ca(CO 2 ) are taken and agent contains additionally calcium phosphate CaPO 4  as a stimulating agent of regenerative processes and calcium fluoride CaF 2 , magnesium Mg and manganese Mn also taken in the definite ratio of components. Invention provides reducing time treatment and enhanced effectiveness of treatment. EFFECT: enhanced and valuable properties of agent. 1 ex
The pathophysiology of endometriosis remains unclear. Retrograde menstruation could be a phenomenon that initiates the process, but it may not explain the entire pathophysiology of endometriosis. Current evidence suggests that endometriosis is a type of chronic inflammatory disease. Many conditions that affect the vascular endothelium, including atherosclerosis, cardiovascular disease and pre-eclampsia, have been shown to be associated with endometriosis. Evidence to date suggests a complex interaction in endometriosis between angiogenesis, hormones and immunological changes stemming from chronic inflammation, with the inflammatory cells releasing cytokines and chemokines including tumour necrosis factor-α (TNF-α). Indeed, TNF-α is considered to be one of the possible markers of endometriosis in the blood, endometrium or menstrual blood. We emphasize the importance of pursuing research for novel and safer anti-inflammatory and immunomodulatory drugs that can be used by patients with endometriosis on a long-term basis.
Described is use of Salvia hispanica L. (Chia) for controlling, in one embodiment reducing, blood glucose levels, preferably post-prandial blood glucose levels. This is useful in both non-diabetic and diabetic individuals, but especially in diabetic individuals. Also described is the use of chia in reducing postprandial blood glucose, insulin sensitivity, blood pressure, and oxidative stress in such individuals. The present invention further found that Chia can be used to improve endothelial function, coagulation, fibrinolysis and iron status. The present invention further encompasses the use of Chia in the treatment and/or management of diabetes and/or the treatment and management of diabetes associated conditions or risk factors, such as one or more of the following: blood pressure and blood glucose levels, post-prandial glycemia, inflammatory factors (C-reactive protein), coagulation (fibrinogen, factor VIII, von Willenbrand factor), and fibronolytic factors (such as t-PA), iron status and endothelial function, (such as increase in nitric oxide generation). In one embodiment the invention relates to dietary approaches to such treatment and management.
Sham Stimulation mimics the physical effects of stimulation, with up to one minute of stimulation during the session. Sham stimulation is delivered using the XCSITE100 Stimulator Sham.
The Alzheimer specialized teams provide "occupational" therapy to maintain or restore the functional capacities of patients. After a deep evaluation of the expectations and needs of patients and their caregivers, the therapists propose to work one or more specific activities that were once pleasant through 12 to 15 sessions at home over 3 months. They also advise individuals to optimize home safety. A pilot observational study that we conducted reported a significant reduction in behavioral disorders of patients during the first 3 months followed by stability. According to the therapists involved in this study, the 3-month format is considered too short to produce perennial benefits; stimulation is often interrupted at the end of the 3 months, which creates a break in management that can be deleterious for patients.

The main objective of this trial is to evaluate the effectiveness of the maintenance of occupational therapy for 4 months beyond the three months provided for in the regulatory framework for the management of demented patients, Measured by the neuropsychiatric inventory (NPI). The secondary objectives will be to study the efficacy on other clinical criteria but also to carry out an economic evaluation of the maintenance of occupational therapy.
Congenital anomalies of the kidney and urinary tract (CAKUT) are primarily causal for end-stage renal disease and have significant implications for long-term survival. A total of 39 healthy controls and 94 children with chronic kidney disease (CKD) were enrolled (3-12 years old as children, 13-18 years old as adolescents), who were divided into CAKUT and Non-CAKUT according to the etiology of CKD. CKD group was further classified according to estimating glomerular filtration rate (eGFR). Circulating levels of inflammatory markers such as interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), monocyte chemokine-1 (MCP-1), and transforming growth factor-β1 (TGF-β1) were analyzed. The relationship between these inflammatory markers with eGFR and the kidney injury parameter (urine protein) was investigated to assess their potential as early markers of disease progression. All circulating levels of these inflammatory cytokines were increased in CKD patients (including CAKUT and Non-CAKUT) compared with healthy subjects. The circulating levels of MCP-1 and TGF-β1 were increased in CAKUT adolescents compared with CAKUT children. In CAKUT children, levels of MCP-1 and TGF-β1 increased as CKD progressed, and MCP-1 and TGF-β1 were negatively and significantly correlated with eGFR and positively with urine protein. MCP-1 and TGF-β1 may contribute to the early detection of CKD and disease stage/progression in CAKUT children.
INTRODUCTION: Bitemporal hemianopia is usually caused by chiasmal pathology. Rarely, chorioretinal lesions may develop symmetrically in both eyes and mimic chiasmopathy.
METHODS: This case series included three patients who presented to a tertiary neuro-ophthalmology centre with bitemporal hemianopic defects between 2021 and 2023 and were subsequently diagnosed with bilateral chorioretinopathy. All patients received comprehensive examinations from a fellowship-trained neuro-ophthalmologist and uveitis specialist to rule out other causes of visual dysfunction.
RESULTS: Three males aged 64, 62, and 72 years were included. All patients showed bitemporal hemianopic defects crossing the vertical midline on automated perimetry and binasal thinning of the macular ganglion cell complex on spectral-domain optical coherence tomography (OCT). Fundus autofluorescence (FAF) showed classical features of acute zonal occult outer retinopathy (AZOOR) in two patients and central serous chorioretinopathy (CSCR) in another. AZOOR diagnosis was preceded by neuroimaging in both cases, whereas the patient with CSCR had longstanding, electroretinography-confirmed lesions and did not require neuroimaging. Fundus appearance and visual field defects remained stable in all patients across 3-6 months of follow-up.
CONCLUSIONS: Bilateral chorioretinopathy should be considered in the differential diagnosis of bitemporal hemianopia in specific cases, including when visual field defects cross the vertical midline and when neuroimaging fails to reveal chiasmal pathology. FAF and macular OCT have high diagnostic yield as initial investigations.
FIELD: medicine. SUBSTANCE: method involves applying complex treatment including gradual warming of the injured extremity, infusion therapy and peridural anesthesia. The treatment starts with carrying out prolonged epidural anesthesia using lidocaine solution immediately on patient admission. Peridural space puncturing and catheterization is applied at the level of T11-T12. The catheter is cranially introduced into two segments. Lidocaine is infused first at a dose of 6 mg/kg and then 2 mg/kg every 3 h during 3 days. EFFECT: enhanced effectiveness of treatment; accelerated blood circulation restoration in injured extremity.
The low-fat comparison group will also be provided all their food. Their diet will also be restricted in calories and have the same level of protein, but it will be lower in fat and higher in carbohydrate. The low-fat diet will consist of approximately 25% fat, with the remaining calories coming from carbohydrates (approximately 55% after accounting for protein at around 20%). Added sugars will be kept relatively low (less than 25 g/day) with a focus on unprocessed carbohydrate-rich foods. Saturated fat will be limited to less than 10% of total energy, with a focus on unsaturated fat sources.
Ciprofloxacin administered intravenously and/or orally was compared to a cephalosporin for treatment of cUTI and pyelonephritis in pediatric patients 1 to 17 years of age (mean age of 6 ± 4 years). The trial was conducted in the US, Canada, Argentina, Peru, Costa Rica, Mexico, South Africa, and Germany. The duration of therapy was 10 to 21 days (mean duration of treatment was 11 days with a range of 1 to 88 days). The primary objective of the study was to assess musculoskeletal and neurological safety.

Patients were evaluated for clinical success and bacteriological eradication of the baseline organism(s) with no new infection or superinfection at 5 to 9 days post-therapy (Test of Cure or TOC). The Per Protocol population had a causative organism(s) with protocol specified colony count(s) at baseline, no protocol violation, and no premature discontinuation or loss to follow-up (among other criteria).

The clinical success and bacteriologic eradication rates in the Per Protocol population were similar between ciprofloxacin and the comparator group as shown below.
NEW MATERIAL:A compound expressed by formula I (R1 is 10-26C alkyl; R2 is 9-25C alkyl; X and Y are H or saccharide residue and both will not be H at the same time). EXAMPLE:N-( 3-Hexadecyloxy-2-hydroxypropyl)-N-(2-O-D-glucopyranosyl)ethyl )hexadecanamide. USE:A dermal agent for external use. PREPARATION:For example, a glycidyl ether expressed by formula II is reacted with ethanolamine and only the amino group of the resultant product is selective ly acylated to provide a compound expressed by formula III. Either of primary and secondary hydroxyl groups in the resultant compound expressed by formula III is then protected and the protected compound is subsequently reacted with O-(2,3,4,6-tetra-O-benzyl-alpha-D-glycopyranosyl)trichloroacet-imidate in the presence of boron trifluoride etherate. The protecting group is subsequently removed to afford the aimed compound expressed by formula I.
The invention relates to the field of pharmaceutical preparations, particularly an elcatonin pharmaceutical composition and a preparation method thereof. The elcatonin injection comprises elcatonin, sodium citrate, citric acid and sodium chloride. The preparation method comprises the following steps: dissolving sodium citrate in a 0.9% sodium chloride injection to obtain a sodium citrate solution, dissolving citric acid in injection water to obtain a citric acid solution, regulating the pH value of the sodium citrate solution to 5.0-6.5 with the citric acid solution, diluting to the specified volume with the 0.9 sodium chloride injection, adding elcatonin, filtering, filling and rolling covers. The prescription and technique of the elcatonin injection is simple. The invention lowers the cost and is suitable for industrial production. The pH value stability and active component content stability can be kept within the effective period.
The safety and efficacy of once-daily FORTEO, median exposure of 10 months, were examined in a double-blind, multicenter, placebo-controlled clinical study of 437 men with either primary (idiopathic) or hypogonadal osteoporosis. In this study, 151 men received 20 mcg of FORTEO given subcutaneously once daily. All men received 1000 mg of calcium and at least 400 IU of vitamin D per day. The primary efficacy endpoint was change in lumbar spine BMD. 

FORTEO increased lumbar spine BMD in men with primary or hypogonadal osteoporosis. Statistically significant increases were seen at 3 months and continued throughout the treatment period. FORTEO was effective in increasing lumbar spine BMD regardless of age, baseline rate of bone turnover, and baseline BMD. The effects of FORTEO at additional skeletal sites are shown in Table 4. 

FORTEO treatment for a median of 10 months increased lumbar spine BMD from baseline in 94% of men treated. Fifty-three percent of patients treated with FORTEO achieved at least a 5% increase in spine BMD, and 14% gained 10% or more.
Participants complete a total of 3-9 sessions with researchers and sessions will be conducted remotely via telephone or secure video platform (Kara Connect). In the baseline session, questionnaires are administered and the individual intrusive trauma memories will be logged for monitoring their frequency in a daily diary. Participants will record their intrusive memories in the daily diary for at least one week (Week -1) before commencing the intervention. In the first intervention session, a memory will be selected and targeted with the intervention (memory reminder followed by 25 min gameplay with mental rotation). We aim to deliver a second intervention session soon after the first (within approx. one week), targeting the same or a different intrusive memory. Participants are instructed that they may continue using the technique self-guided after the first intervention session, and they may opt for additional intervention sessions with remote researcher support (maximum 6 intervention sessions). Participants continue to monitor the frequency of both targeted and non-targeted intrusive memories in the daily diary throughout Weeks 0-5. Follow-up questionnaires are completed at Week 1, 1-month, and 3-months after the second intervention session. The primary outcome is change in total number of intrusive memories from the baseline week (Week -1) to the fifth week after the second intervention session (Week 5). Participants will also monitor the frequency of their intrusive memories for one week at the 3-month follow-up. The investigators note that the intended time-frames may differ slightly across participants depending on availability and the practicalities of remote delivery.
The present invention relates to sealed soft package type hemodialysis liquid, a special packaging bag and the application thereof. The present invention is characterized in that the liquid is composed of liquid A and liquid B, wherein the liquid A and the liquid B are independent sealed soft package type liquid, and the liquid A and the liquid B can be mixed into the hemodialysis liquid by a special dialysis machine. The concentration of the potassium ion K<+> of the mixed hemodialysis liquid is more than or equal to 3 to prevent a patient from generating low-potassium symptom, or the concentration of sodium ions Na<+> is more than or equal to 145 to prevent the patient from generating unbalance syndrome. The patient's ability of enduring ultra-filtration is enhanced. In the present invention, the hemodialysis liquid is isolated from air in the entire process of dialysis, and accordingly, CO2 in the hemodialysis liquid can not escape, the concentration of sodium hydrogen carbonate is constant, the quality of the hemodialysis liquid is ensured. Meanwhile, the dependence on preparation departments is reduced; the contradiction of supply and demand is avoided.
This study explores the use of digital technologies in assessing frailty and Quality of Life (QoL) in older adults within the Italian healthcare system. The "Prevention Days for Healthy Ageing" organized by the Reference Site "Roma - Tor Vergata" employed online tools, Sunfrail+ and SF-12, for assessing frailty and QoL in 136 older adults. Sunfrail+ generated an average of 2.71 positive alerts at baseline and 0.77 in the 2-level. Associations were found between positive alerts and SF-12 physical/mental indexes. Correlations existed between Sunfrail secondary tools (e.g., Time Up and Go) and QoL indexes. Sunfrail+ is a valuable tool for Family and Community Nurses and proposes future integration into a streamlined app for self-administration by seniors, promoting timely interventions.